Theranexus (EPA:ALTHX) | WebDisclosure

Basculer en Français

10605	Companies
225020	Keywords
153740	Articles
119079	Press releases

Home
Companies
Theranexus

PRESS RELEASE

published on 04/23/2024 at 07:30, 2 years 1 month ago

Theranexus, Diverchim and Inserm awarded EUR 4.7 million in funding under the "Innovations in biotherapies and biomanufacturing" call for proposals from France 2030 to develop a novel antisense oligonucleotide
Theranexus, Diverchim, and Inserm's ARNA laboratory receive €4.7 million funding from French Government to develop autophagy activation therapy for rare neurological diseases under the PickASO project in collaboration with France 2030

Theranexus Diverchim Autophagy Activation Therapy Inserm PickASO Project
BRIEF

published on 04/18/2024 at 18:05, 2 years 2 months ago

Theranexus et BBDF annoncent des résultats positifs pour l'étude de phase 1/2 de Batten-1

Étude Clinique Maladies Rares Theranexus Maladie De Batten CLN3 Batten-1
BRIEF

published on 04/18/2024 at 18:05, 2 years 2 months ago

Theranexus and BBDF Announce Positive Results for Batten-1 Phase 1/2 Study

Clinical Study Rare Diseases Theranexus Batten-1 Batten Disease CLN3
PRESS RELEASE

published on 04/18/2024 at 18:00, 2 years 2 months ago

Theranexus et BBDF annoncent les données finales et positives de sécurité et d'efficacité de Batten-1 dans l'étude de phase 1/2
Theranexus et la Fondation BBDF annoncent des données positives sur la stabilisation des symptômes moteurs chez les patients jeunes adultes atteints de la maladie de Batten CLN3 après 18 mois de traitement

Theranexus Fondation BBDF Maladie De Batten Stabilisation Symptômes Moteurs Traitement Batten-1
PRESS RELEASE

published on 04/18/2024 at 18:00, 2 years 2 months ago

Theranexus and BBDF announce final and positive safety and efficacy data in the Phase I/II trial testing Batten-1
Theranexus and BBDF announce positive final results after 18-month Phase I/II trial of Batten-1 in juvenile Batten disease (CLN3) patients, showing stabilization of motor symptoms progression in young adults

Theranexus Batten-1 BBDF Juvenile Batten Disease Phase I/II Trial
PRESS RELEASE

published on 05/10/2023 at 16:59, 3 years 1 month ago

Theranexus et BBDF obtiennent l'accord de la FDA sur les critères d'efficacité de l'étude de phase 3 de Batten-1 dans la maladie de Batten CLN3

Accesswire

Published on 06/22/2026 at 03:00, 3 hours 38 minutes ago

Tunkillia Pre-Feasibility Study Begins
Published on 06/20/2026 at 01:00, 2 days 5 hours ago

Onco-Innovations Announces Non-Brokered LIFE Offering
Published on 06/20/2026 at 00:00, 2 days 6 hours ago

Onco-Innovations Reports Completion of 300g Active Pharmaceutical Ingredient for ONC010 Scale-Up Supporting IND-Enabling Development
Published on 06/19/2026 at 04:30, 3 days 2 hours ago

Uraniumx Discovery Corp. Announces Acquisition of Common Shares of Gold'n Futures Mineral Corp
Published on 06/19/2026 at 01:20, 3 days 5 hours ago

American Hotel Income Properties REIT LP Reports Voting Results of Annual and Special Meeting

View all ACCESSWIRE

EQS Group

Published on 06/22/2026 at 06:05, 32 minutes ago

adidas and GLO Brands B.V., debuts ADIDAS PRO WORK, a new safety footwear range, combining performance, protection and style for the modern worksite
Published on 06/22/2026 at 04:05, 2 hours 32 minutes ago

Optro Accelerates Global Growth with Singapore Hub, Delivering Agentic GRC to APAC Enterprises
Published on 06/20/2026 at 21:25, 1 day 9 hours ago

VIVATECH 2026 CELEBRATES ITS 10TH ANNIVERSARY WITH A RECORD EDITION SURPASSING 200,000 VISITORS
Published on 06/20/2026 at 06:00, 2 days ago

Successful debut of International Symposium on Emergency Response and Aeromedical Services in Hong Kong
Published on 06/19/2026 at 20:17, 2 days 10 hours ago

2CRSi SA: 2CRSi Responds Point-by-Point to the Grizzly Research Report and Reaffirms the Reality of Its Business Operations

Les Echos

Published on 06/19/2026 at 19:33, 2 days 11 hours ago

Déclaration hebdomadaire d'opérations effectuées du 15 au 19 juin 2026
Published on 06/19/2026 at 19:33, 2 days 11 hours ago

Disclosure of transactions in own shares from June 15 to June 19, 2026
Published on 06/19/2026 at 19:23, 2 days 11 hours ago

Imerys-06-2026-communique-capital-droits-de-vote-au-31-mai-2026
Published on 06/19/2026 at 19:23, 2 days 11 hours ago

Imerys-06-2026-information-share-capital-and-voting-rights-as-of-31-May-2026
Published on 06/19/2026 at 19:05, 2 days 11 hours ago

CP - Changement de gouvernance

View all LES ECHOS COMFI WIRE